Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease

• Status: Terminated
• Trial end date: 2015-06-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether BMS-813160 will reduce the amount of protein loss in the urine of subjects with type 2 diabetes and diabetic kidney disease

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Clinical diagnosis of type 2 diabetes mellitus with macroalbuminuria (UACR between 200 and 3500 mg/g)

• Background angiotensin converting enzyme inhibitor (ACEI) or angiotensin-receptor blocker (ARB) therapy

Exclusion Criteria:

• Clinical diagnosis of type 1 diabetes

• Unstable cardiovascular, metabolic, or other chronic disease status

• Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2

• High risk of infection or immune compromise

• Clinically significant ECG conduction abnormalities

• Drugs with significant potential to affect BMS-813160 exposure